Literature DB >> 8426994

Management of recurrent and metastatic colorectal carcinoma.

H J Asbun1, K S Hughes.   

Abstract

When metastatic or recurrent disease from colorectal carcinoma is detected, the surgeon must decide whether a patient is a candidate for resection. Although long-term survival after resection is not optimal, the relegation of patients to nonresective treatment means denying them the only chance for cure currently available. When isolated disease involving the liver, lung, or region of the primary carcinoma is documented, curative resection must be considered. Symptomatic patients may also obtain maximal palliation from resection, diversion, or a bypass procedure. Chemotherapy for the treatment of recurrent disease is palliative and probably should be considered only within clinical trials. Future alternative methods of treatment or new chemotherapeutic regimens need to be studied to improve survival and quality of life.

Entities:  

Mesh:

Year:  1993        PMID: 8426994     DOI: 10.1016/s0039-6109(16)45934-7

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  6 in total

1.  Metastatic factors for Krukenberg tumor: a clinical study on 102 cases.

Authors:  Li Qiu; Ting Yang; Xue-Hua Shan; Ming-Bai Hu; Yan Li
Journal:  Med Oncol       Date:  2010-07-07       Impact factor: 3.064

2.  Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience.

Authors:  Eduard L A R Mutsaerts; Serge van Ruth; Frans A N Zoetmulder; Emiel J T Rutgers; Augustinus A M Hart; Frits van Coevorden
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

3.  Surgical treatment for the recurrence of colorectal cancer.

Authors:  Y Yamamoto; H Imai; S Iwamoto; Y Kasai; T Tsunoda
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Intraoperative ultrasonography in the diagnosis of hepatic metastases during surgery for colorectal cancer.

Authors:  N Takeuchi; J M Ramirez; N J Mortensen; R Cobb; T Whittlestone
Journal:  Int J Colorectal Dis       Date:  1996       Impact factor: 2.571

5.  Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.

Authors:  K F Yoong; D H Adams
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

Review 6.  The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review.

Authors:  Ondřej Kubeček; Jan Laco; Jiří Špaček; Jiří Petera; Jindřich Kopecký; Alena Kubečková; Stanislav Filip
Journal:  Clin Exp Metastasis       Date:  2017-07-20       Impact factor: 5.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.